UTHR · CIK 0001082554 · operating
United Therapeutics is a biotechnology company focused on treatments for chronic and life-threatening diseases, with primary emphasis on pulmonary arterial hypertension (PAH). The company's commercial portfolio includes several formulations of treprostinil—marketed as Remodulin (injection), Tyvaso (inhaled solution), and Tyvaso DPI (inhaled dry powder)—which work as prostacyclin receptor agonists to improve exercise capacity and reduce symptoms in PAH patients. The company also markets Orenitram (oral treprostinil), Adcirca (a PDE-5 inhibitor), and Unituxin (dinutuximab), a monoclonal antibody used in high-risk neuroblastoma treatment. Additionally, United Therapeutics manufactures the Remunity Pump, a device for subcutaneous treprostinil delivery.
The company maintains a pipeline of development-stage programs including RemoPro and Ralinepag for PAH, Aurora-GT (a gene therapy product targeting pulmonary vascular disease), and xenograft organ products. United Therapeutics operates strategic partnerships with MannKind Corporation on inhalation powder delivery systems and with Arena Pharmaceuticals on Ralinepag development.
Headquartered in Silver Spring, Maryland, the company operates with approximately 1,305 full-time employees and maintains an international commercial presence. United Therapeutics was incorporated in Delaware in 1996 and is listed on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $27.86 | $30.13 | +13.1% | |
| 2024 | $24.64 | $26.44 | +24.4% | |
| 2023 | $19.81 | $21.04 | +32.1% | |
| 2022 | $15.00 | $15.98 | +49.1% | |
| 2021 | $10.06 | $10.60 | -12.8% | |
| 2020 | $11.54 | $11.65 | +861.7% | |
| 2019 | $1.20 | $1.20 | -18.9% | |
| 2018 | $1.48 | $1.50 | +244.2% | |
| 2017 | $0.43 | $0.44 | -82.3% | |
| 2016 | $2.43 | $2.61 | +15.7% | |
| 2015 | $2.10 | $2.29 | -3.2% | |
| 2014 | $2.17 | $2.44 | +461.7% | |
| 2013 | $-0.60 | $-0.60 | -137.5% | |
| 2012 | $1.60 | $1.65 | +107.8% | |
| 2011 | $0.77 | $0.79 | -56.7% | |
| 2010 | $1.78 | $1.89 | — |